Theriva Biologics, Inc.: current assets
Current assets for Theriva Biologics, Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Theriva Biologics, Inc. financial histories
What this measure means
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
Exact concept: us-gaap:AssetsCurrent. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2010-12-31 to 2025-12-31. The SEC response was captured on 2026-09-20.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| At date | 2025-12-31 | 17,467,000 | USD | 2026-03-12 | 10-K · 0001104659-26-026767 |
| At date | 2024-12-31 | 16,281,000 | USD | 2026-03-12 | 10-K · 0001104659-26-026767 |
| At date | 2023-12-31 | 27,403,000 | USD | 2025-03-06 | 10-K · 0001410578-25-000285 |
| At date | 2022-12-31 | 45,520,000 | USD | 2024-03-25 | 10-K · 0001410578-24-000293 |
| At date | 2022-09-30 | 52,731,000 | USD | 2023-03-30 | 10-K · 0001410578-23-000428 |
| At date | 2022-06-30 | 54,888,000 | USD | 2023-03-30 | 10-K · 0001410578-23-000428 |
| At date | 2021-12-31 | 68,858,000 | USD | 2023-03-30 | 10-K · 0001410578-23-000428 |
| At date | 2020-12-31 | 7,934,000 | USD | 2022-03-16 | 10-K · 0001410578-22-000405 |
| At date | 2019-12-31 | 16,426,000 | USD | 2021-03-04 | 10-K · 0001104659-21-032150 |
| At date | 2018-12-31 | 29,511,000 | USD | 2020-02-20 | 10-K · 0001104659-20-023415 |
| At date | 2017-12-31 | 17,943,000 | USD | 2019-02-27 | 10-K · 0001144204-19-010592 |
| At date | 2016-12-31 | 21,570,000 | USD | 2018-02-22 | 10-K · 0001144204-18-010286 |
| At date | 2015-12-31 | 30,337,000 | USD | 2017-03-02 | 10-K · 0001144204-17-012545 |
| At date | 2014-12-31 | 19,073,000 | USD | 2016-03-10 | 10-K · 0001144204-16-087267 |
| At date | 2013-12-31 | 16,216,000 | USD | 2015-03-16 | 10-K · 0001144204-15-016433 |
| At date | 2012-12-31 | 12,463,000 | USD | 2014-03-31 | 10-K · 0001144204-14-019505 |
| At date | 2011-12-31 | 7,122,000 | USD | 2013-04-16 | 10-K · 0001144204-13-022048 |
| At date | 2010-12-31 | 3,545,000 | USD | 2012-05-11 | 10-K/A · 0001144204-12-028166 |
Related financial histories
- Theriva Biologics, Inc.: total assets
- Theriva Biologics, Inc.: total liabilities
- Theriva Biologics, Inc.: stockholders equity
- Theriva Biologics, Inc.: cash and cash equivalents
- Theriva Biologics, Inc.: net income or loss
- Theriva Biologics, Inc.: operating cash flow
- Theriva Biologics, Inc.: capital expenditure payments
- Theriva Biologics, Inc.: financing cash flow
- Theriva Biologics, Inc.: investing cash flow
- Theriva Biologics, Inc.: retained earnings or deficit
- Theriva Biologics, Inc.: basic weighted-average shares
- Theriva Biologics, Inc.: diluted weighted-average shares
- Theriva Biologics, Inc.: basic earnings per share
- Theriva Biologics, Inc.: diluted earnings per share
- Theriva Biologics, Inc.: income tax expense or benefit
- Theriva Biologics, Inc.: net property, plant and equipment
- Theriva Biologics, Inc.: share-based compensation expense
- Theriva Biologics, Inc.: operating income or loss
- Theriva Biologics, Inc.: current liabilities
- Theriva Biologics, Inc.: current accounts payable
- Theriva Biologics, Inc.: goodwill carrying amount
- Theriva Biologics, Inc.: net current accounts receivable
- Theriva Biologics, Inc.: operating expenses
- Theriva Biologics, Inc.: research and development expense
Inspect the source
- Entity
- Theriva Biologics, Inc. / CIK 0000894158
- Captured
- 2026-09-20T05:04:09.087Z
- SEC response SHA-256
0de75e0c14bf762eac1125a82293caea25684675d03e66311f5d17f900dbb0a7
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0000894158.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))